A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).
EP. 1: Adjuvant Treatment of EGFR+ NSCLC: Standard of Care
EP. 2: Ground-Breaking Data: Phase 3 ADAURA Trial
EP. 3: Third-Generation Versus Earlier-Generation Agents
EP. 4: ADAURA Phase III Trial Data: Practice Changing?
2 Clarke Drive Cranbury, NJ 08512